Analysis of HBX gene in PBMC from chronic hepatitis B patients with undetectable serum HBV DNA after treatment by nucleoside analogues
10.3760/cma.j.issn.1003-9279.2017.03.016
- VernacularTitle: 经NAs治疗显效慢乙肝患者PBMC中HBX基因检测及临床意义
- Author:
Yiran SONG
1
;
Ge LI
2
;
Hang ZHANG
3
;
Jie WANG
2
;
Yanming JIANG
2
;
Yanhua KANG
3
;
Yidan GAO
3
;
Binbin ZHANG
3
;
Gongying CHEN
2
,
4
Author Information
1. Zhejiang Chinese Medical University, Hangzhou 310053, China
2. The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310053, China
3. Hangzhou Normal University, Hangzhou 310053, China
4. Hangzhou Normal University, Hangzhou 310053, China
- Publication Type:Journal Article
- Keywords:
PCR;
Hepatitis B;
Chronic;
DNA
- From:
Chinese Journal of Experimental and Clinical Virology
2017;31(3):253-256
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Study the clinical significance of HBX gene detection, sequence analysis in peripheral blood mononuclear cell(PBMC) of chronic hepatitis B(CHB) patients with serum HBV DNA negative conversion after treatment by nucleoside analogues(NAs).
Methods:Detected and analyzed the HBX gene sequence by real time PCR in PBMC of 60 patients with CHB including some with cirrhosis or hepatocellular carcinoma(HCC), all the serum HBV DNA had turned negative after treatment by NAs, and explore the clinical significance of the HBX gene.
Results:HBX genes were detected in 37 cases(61.67%, 37/60). HBX positive rates of PBMC in HCC and cirrhosis patients were higher than that of CHB patients(P=0.000, P=0.010). HBX △120, HBX△129, HBX△131 truncations were detected in two HCC and one CHB cases. Two hotspot mutation including A389T/G391A, T380C had been found, and A389T/G391A double mutation in HCC patients was significantly higher than that in CHB patients(P=0.021). In cirrhosis and HCC patients, T380C mutation rate in HBeAg(-) cases was higher than that in HBeAg(+ ) cases(P=0.035).
Conclusions:In patients with serum HBV DNA negative conversion after treatment by NAs, PBMC HBX gene positive rates in cirrhosis or HCC cases are higher than that in CHB cases. A389T/G391A double mutation rate in HCC cases is significantly higher than that in CHB cases. In cirrhosis and HCC patients, T380C mutation rate in HBeAg(-) cases is higher than that in HBeAg(+ ) cases.
